Current trends in transplantation and immunosuppressive treatment

Drug News and Perspectives

Volumn 16, Issue 5, 2003, Pages 332-336

  Máñez, Rafael ^a  

^a Complexo Hospitalario Juan Canalejo ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; A 228839; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; GENZ 29155; IMMUNOSUPPRESSIVE AGENT; LF 15 0195; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NC 1153; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; CARDIOVASCULAR RISK; CLINICAL IMMUNOLOGY; CONFERENCE PAPER; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GENOMICS; GRAFT FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MEDICAL SOCIETY; PANCREAS ISLET TRANSPLANTATION; SIDE EFFECT; TRANSPLANTATION;

AMIDES; BENZOPHENONES; BENZYLAMINES; GENOMICS; GUANIDINES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; ISLETS OF LANGERHANS TRANSPLANTATION; JANUS KINASE 3; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; METHIONINE; ORGAN TRANSPLANTATION; PROTEIN-TYROSINE KINASES; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141839806     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Bresnahan, B. et al. Short-term benefit of tacrolimus vs. cyclosporine therapy after renal transplantation: An analysis of UNOS/OPTN database. Abst. 1213.
2. Aswad, S. et al. Cyclosporine vs. tacrolimus in renal transplantation: Five-year recipient: outcomes. Abst. 1216.
3. Strologo, L.D. et al. C2 monitoring: A reliable tool also in young renal transplanted children. Abst. 54.
4. Scholten, E.M. et al. Calcineurin-inhibitor nephrotoxicity and efficacy study: The Cannes Trial. Abst. 1569.
5. Larson, T.S. et al. Avoiding calcineurin-inhibitors in renal transplantation: A randomized trial of sirolimus vs tacrolimus. Abst. 1261.
6. Budde, K. et al. Stable renal transplant patients on mycophenolate mofetil can be safely switched to enteric-coated mycophenolate sodium: 12-month data of a prospective randomized trial. Abst. 1568.
7. Kandaswamy, R. et al. A prospective randomized study of cyclosporine (CSA)/cell-cept (MMF) vs. Tacrolimus (TAC)/sirolimus (SIR) with rapid discontinuation of prednisone (p). Abst. 182.
8. Borrows, R. et al. Steroid avoidance with tacrolimus and mycophonolate mofetil in renal transplantation. Abst. 772.
9. Woodle, E.S. et al. A prospective, randomized, double blind, multicenter trial of early (7 day) corticosteroid cessation vs long-term low-dose corticosteroid therapy under tacrolimus and mycophenolate mofetil therapy with antibody induction. Abst. 183.
10. Wlodarczyk, Z. et al. Freedom from rejection and stable renal function are excellent criteria for steroid withdrawal in tacrolimus therapy. Abst. 1575.
11. Watarai, Y. et al. High incidence of graft fibrosis after steroid withdrawal in pediatric renal tranplantation. Abst. 58.
12. Kerman, R.H. et al. Choice of induction therapy for sirolimus treated renal recipients based upon immune risk factors. Abst. 814.
13. Boillot, O. et al. Effective and safe steroid-free immunosuppression with a tacrolimus/daclizumab regimen after liver transplantation. Abst. 671.
14. Tzakis, A.G. et al. Campath 1h with tacrolimus immunosuppression in adult liver allotransplantation: our experience with 19 cases. Abst. 678.
15. Lucey, M.R. et al. Impact of tacrolimus (tac) versus cyclosporine (csa) on long-term renal function and cardiovascular (cv) risk following liver transplantation. Abst. 676.
16. Lam, P. et al. The efficacy of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Abst. 674.
17. Bahra, M. et al. Pegylated interferon alfa-2b plus ribavirin in patients with hepatitis C reinfection after OLT. Abst. 1097.
18. Rahim, N.A. et al. Increased adherence to treatment of recurrent hepatitis C after liver transplantation by using growth factors. Abst. 1096.
19. Zuckerman, A. et al. Sirolimus (rapamycin) as rescue therapy in heart transplant recipients with calcineurin induced renal dysfunction. Abst. 61.
20. Mancini, D. et al. 24-Month results of a multicenter study of everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Abst. 1553.
21. Hare, J. et al. Therapeutic drug monitoring of everolimus may be beneficial in de novo heart transplantation. Abst. 63.
22. Hill, J.A. et al. Reduced incidence of CMV infection in heart transplant patients treated with everolimus. Abst. 67.
23. White, M. et al. Prograf decreases plasma cholesterol, creatinine and uric acid in heart transplant recipients with treated but persisting mild dyslipidemia: The Canadian multicenter randomized trial of Prograf versus Neoral. Abst. 64.
24. Zucker, M. et al. Sirolimus-tacrolimus based immunosuppression vs. traditional immunosuppression in de novo heart transplant recipients - A single center analysis. Abst. 69.
25. Meiser, B. et al. Combination of low dose tacrolimus and sirolimus effectively prevents rejection and viral infection after HTx. Abst. 65.
26. Zuckermann, A. et al. Long-term follow-up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. Abst. 21.
27. Zamora, M.R. et al. Valganciclovir for the prevention of cytomegalovirus following lung transplantation: efficacy and optimal length of therapy. Abst. 26.
28. Bolin, L.M. et al. Valganciclovir for CMV prophylaxis after lung transplantation: Interim results. Abst. 698.
29. Sindhi, R. et al. Thymoglobulin (RATG) preconditioning enhances (TAC) tacrolimus-induced inhibition of lymphocyte function in pediatric liver and intestinal recipients. Abst. 1175.
30. Sindhi, R. et al. Effect of thymoglobulin preconditioning and tacrolimus/sirolimus monotherapy on lymphocyte subpopulation distribution and function in children with abdominal transplants. Abst. 159.
31. Shapiro, J. et al. International multicenter trial of islet transplantation using the Edmonton protocol in patients with type 1 diabetes. Abst. 3.
32. Lakey, J.R.T. et al. Standardization of human islet isolation for a international multi-center transplant trial. Abst. 571.
33. Borie, D.C. et al. Targeted inhibition of Jak3 with cp-690,550 significantly prolongs allograft survival in a nonhuman primate model of renal transplantation. Abst. 4.
34. Kirken, R. NC1153 is a novel water soluble mannich base that selectively inhibits Janus tyrosine kinase (Jak)3 and prolongs allograft survival. Abst. 461.
35. Sho, M. et al. Significance and therapeutic potential of targeting TNF-alpha signaling in alloimmune response. Abst. 592.
36. Zhou, D. et al. Interaction of LF 15-0195, a novel immunosuppressive agent with cyclosporine A, FK506 and rapamycin in a mouse cardiac allograft model. Abst. 40.
37. Li, M. et al. LF15-0195 promotes tolerogenic dendritic cells by inhibiting IKK activity. Abst. 593.
38. Min, W-P. et al. Preventing allograft rejection by in vitro generated suppressor dendritic cells and T regulatory cells. Abst. 20.
39. Feng, P. et al. Immunotoxins DT390-IL-2 and DT390-RANTES selectively inhibit alloreactive T cell proliferation in mixed lymphocyte reaction. Abst. 594.
40. Si, M-S. et al. Farnesyltransferase inhibition: A novel method of immunomodulation. Abst. 595.
41. Schuler, W. et al. AB1793, a novel, fully human anti-CD154 monoclonal antibody: efficacy in cynomolgus monkey kidney allotransplantation. Abst. 545.
42. Kanmaz, T. et al. Monotherapy with the human anti-CD154 monoclonal antibody ABI793 prolongs allograft survival in rhesus monkeys. Abst. 599.
43. Preston, E.H. et al. Prolonged rejection-free renal allograft survival with the anti-CD154 antibody IDEC-131 combined with donorspecific transfusion (DST) and sirolimus in non-human primates (NHPs). Abst. 600.
44. Yamane, M. et al. Gene profiling after ischemia and reperfusion following lung transplantation in rats. Abst. 1066.
45. Babel, N. et al. Association of cytokine gene polymoprhisms with non-immunological complications in long-term renal transplant patients. Abst. 823.
46. 1 gene polymorphism on long term renal allograft survival. Abst. 275.
47. Einecke, G. et al. No influence of the MDR1 C3435T polymorphisms, the CYP3A4-V-allele or the CYP3A5*3-polymorphism on cyclosporine absorption profiles and outcome in stable renal transplant recipients. Abst. 1069.
48. Anglicheau, D. et al. Impact of the MDR-1 C3435T polymorphism on tacrolimus doses, trough concentrations and delayed graft function in renal transplant recipients. Abst. 700.
49. MacPhee, I.A.M. et al. Tacrolimus pharmacogenetics: A single nucleotide polymorphism associated with cytochrome P4503A5 expression identifies patients who fail to achieve target blood concentrations during the first week after renal transplantation. Abst. 703.
50. Donati, D. et al. Pilot study of lymphocyte depletion induction with thymoglobulin (Thy) followed by sirolimus (SRL) and mycophenolate mofetil (MMF): A calcineurin-inhibitors (C-INH) free, steroid sparing and likely tolerogenic protocol for kidney transplantation (ktx). Abst. 1120.
51. Kirk, A.D. et al. Results from a human tolerance trial using alemztuzumab (campath-1h) with deoxyspergualin (DSG). Abst. 621.